Related references
Note: Only part of the references are listed.Underpowered PANTS: A Response to the Conclusions of Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab
Aleksejs Sazonovs et al.
GASTROENTEROLOGY (2021)
Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach
T. Tsakok et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
Aleksejs Sazonovs et al.
GASTROENTEROLOGY (2020)
Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab
Rebecca D. Powell Doherty et al.
GASTROENTEROLOGY (2020)
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium
Signe Hassler et al.
PLOS MEDICINE (2020)
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials
Dorothea Buck et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials
Dorothea Buck et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Eleven Amino Acids of HLA-DRB1 and Fifteen Amino Acids of HLA-DRB3, 4, and 5 Include Potentially Causal Residues Responsible for the Risk of Childhood Type 1 Diabetes
Lue Ping Zhao et al.
DIABETES (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis
Nick Dand et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis
Jocelyn Quistrebert et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis
Toolika Singh et al.
JOURNAL OF IMMUNOLOGY (2018)
Identification of HLA-DRB1 association to adalimumab immunogenicity
Mohan Liu et al.
PLOS ONE (2018)
Combined effect of glutamine at position 70 of HLA-DRB1 and alanine at position 57 of HLA-DQB1 in type 1 diabetes: An epitope analysis
Petroula Gerasimou et al.
PLOS ONE (2018)
Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study
Alejandro Balsa et al.
RHEUMATOLOGY (2018)
Immunogenicity of biologics in inflammatory bowel disease
Severine Vermeire et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases
Maurizio Benucci et al.
BIOLOGICS-TARGETS & THERAPY (2018)
A reference panel of 64,976 haplotypes for genotype imputation
Shane McCarthy et al.
NATURE GENETICS (2016)
Next-generation genotype imputation service and methods
Sayantan Das et al.
NATURE GENETICS (2016)
Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Emilie M. J. van Brummelen et al.
ONCOLOGIST (2016)
Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register
I. Y. K. Iskandar et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Immunogenicity to infliximab is associated with HLA-DRB1
Thomas Billiet et al.
GUT (2015)
Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients
Karien Bloem et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2015)
High-density mapping of the MHC identifies a shared role for HLA-DRB1☆01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis
Philippe Goyette et al.
NATURE GENETICS (2015)
Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk
Xinli Hu et al.
NATURE GENETICS (2015)
A new classification of HLA-DRB1 alleles based on acid-base properties of the amino acids located at positions 13, 70 and 71: impact on ACPA status or structural progression, and meta-analysis on 1235 patients with rheumatoid from two cohorts (ESPOIR and EAC cohort)
Adeline Ruyssen-Witrand et al.
RMD OPEN (2015)
Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
Jenny Link et al.
PLOS ONE (2014)
Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis One-Year Follow-up
Stef P. Menting et al.
JAMA DERMATOLOGY (2014)
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
Sandra Garces et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
Pauline A. van Schouwenburg et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Imputing Amino Acid Polymorphisms in Human Leukocyte Antigens
Xiaoming Jia et al.
PLOS ONE (2013)
Amino acid position 11 of HLA-DRβ1 is a major determinant of chromosome 6p association with ulcerative colitis
J-P Achkar et al.
GENES AND IMMUNITY (2012)
Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis
Soumya Raychaudhuri et al.
NATURE GENETICS (2012)
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
Lam C. Tsoi et al.
NATURE GENETICS (2012)
Influence of the HLA-DRB1 Genotype on Antibody Development to Interferon Beta in Multiple Sclerosis
Dorothea Buck et al.
ARCHIVES OF NEUROLOGY (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Robust relationship inference in genome-wide association studies
Ani Manichaikul et al.
BIOINFORMATICS (2010)
HLA-DRBI*0401 and HLA-DRBI*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis
Steve Hoffmann et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
PLINK: A tool set for whole-genome association and population-based linkage analyses
Shaun Purcell et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene
RP Nair et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity
MDFS Barbosa et al.
CLINICAL IMMUNOLOGY (2006)
The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRβ1 chain is associated with the clinical course of multiple sclerosis
JM Greer et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis
PJ Foley et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2001)
Share Paper
